ClinicalTrials.Veeva

Menu
S

Southeastern Clinical Research Institute, LLC | Augusta, GA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

KBP-5074
Semaglutide
RGLS8429
Ferric Citrate
Epizon-701
EPN-701
Retatrutide
Finerenone
KRX-0502

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 11 total trials

A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

Primary Objectives* To assess the safety and tolerability of RGLS8429* To assess the impact of RGLS8429 on ADPKD biomarkersSecondary Objectives* To a...

Enrolling
ADPKD
Polycystic Kidney, Autosomal Dominant
Drug: RGLS8429
Drug: Placebo

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finere...

Active, not recruiting
Non-diabetic Chronic Kidney Disease
Drug: Finerenone (BAY94-8862)
Drug: Placebo

The purpose of this study is to determine non-inferiority in safety and efficacy when Quanta SC+ is used in the self-care home environment compared t...

Active, not recruiting
Renal Failure
Device: SC+ Hemodialysis System

This study is an open-label, multi-center study evaluating the clinical utility of Renasight in the diagnosis and management of kidney disease.

Active, not recruiting
Kidney Diseases
Diagnostic Test: Renasight
Locations recently updated

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling
Overweight and Obesity
Drug: Retatrutide
Drug: Placebo

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling
Chronic Kidney Disease
Inflammation
Drug: Placebo (Ziltivekimab B)
Drug: Placebo (Ziltivekimab C)

Trial sponsors

Lilly logo
Novo Nordisk logo
Bayer logo
E
K
K
Natera logo
Q
R

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems